ERBB2 and breast carcinoma: More recently, the BROCADE3 phase III (NCT02163694) trial indicated that the addition of veliparib to carboplatin/paclitaxel considerably improved PFS compared with carboplatin/paclitaxel alone in patients with advanced, unresectable, HER2-negative, gBRCA-mutated breast cancer [30].